New drug trial targets Hard-to-Treat gynecologic cancers
NCT ID NCT07311538
Summary
This study is testing an experimental drug called BRY812 for women with advanced gynecologic cancers that have a specific marker called LIV-1 and have stopped responding to prior treatments. The main goal is to see if the drug can shrink tumors and to understand its safety. About 56 participants with advanced ovarian or endometrial cancer will receive the drug to measure its effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.